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Background
Cerebral control of stress and anxiety involves several neu-
rotransmitter systems. Beside serotonin, noradrenaline or
catecholamines, also neuropeptide systems are consid-
ered to be involved in generating symptoms of anxiety
and stress. These systems act in a circuit connecting amy-
gdaloid and hypothalamic nuclei, the pituitary and adre-
nal glands, regulating the physiological response via
ACTH and corticosterone release.
Methods
In this study, we investigated anxiety and stress-related
behaviour of germ-line prodynorphin knockout (dynKO)
mice. Behavioural data were complemented by in-situ
hybridization analysis of neurotransmitter expression in
anxiety-related brain areas and measurement of corticos-
terone serum levels.
Results
Male dynKO mice exhibited about 2-fold ambulation in
the open field center. DynKO mice showed also more vis-
its (2-fold) and more time (3-fold) spent on open arms of
elevated plus maze test. Significantly higher numbers of
entries, distance and time spent in open lit area (ca. 30%
higher values) in light-dark test were observed in dynKO
as compared to wild-type mice (WT). The anxiolytic phe-
notype of dynKO could be mimicked by injection of the
selective κ antagonists norBNI (10 mg/kg, i.p.) or GNTI (3
nmoles, i.c.) in WT. Applying the specific κ agonist
U50488H (2.5 mg/kg, i.p.) entirely reversed the anxiolytic
phenotype of dynKO. These data are in line with reduced
CRH expression in the hypothalamic paraventricular and
central amygdaloid nuclei and attenuated basal corticos-
teron serum levels. Stress-induced increases in corticoster-
one levels were also less pronounced in dynKO mice;
however, they did not translate into marked differences in
stress-induced immobility.
Conclusion
Taken together, our data suggest anxiogenic effects of
endogenous dynorphin. These effects are mediated by κ
opioid receptors, however not in an immediate manner.
Therefore, we propose a higher order controlling level for
the action of dynorphin, like regulating the expression of
CRH and serum corticosterone levels, which in turn influ-
ence the behaviour of mice.
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